Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019 Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
News
boehringer_biberach_germany_copy

Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019 Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019 Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
News
sandoz

Sandoz is first multinational to secure generic approval under new Chinese guidelines

May 20, 2019 Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin

Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
News
celgene_building

NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma

May 20, 2019 Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
News

Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

May 17, 2019 Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma

The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …
News
lance2

A day in the life: Lance Hill, CEO at Within3

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing A day in the life, Interview, Within3, feature

Could you give a short history of how you came to be in your current role? I’ve spent my entire …
Feature

Insider Interview: Paving paths in prostate cancer

May 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
Feature

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019 Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
News
novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019 Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
News

EUSA Pharma bolsters senior leadership team with two appointments

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eusa Pharma, appointment

Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two …
Appointment
123_dott_paolo_chiesi_550

Paola Chiesi awarded honorary doctorate by Karolinska Institutet

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Paolo Chiesi, Vice President of the Chiesi Group, has been made an Honorary Doctor at the Karolinska Institutet – a …
Appointment
index_ph001

Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

May 15, 2019 Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …
News

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019 Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026